This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Clinical Hematology International Open Access 18 April 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020. [Online ahead of print].
Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, et al. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019;54:1815–26.
Bazarbachi AH, Al Hamed R, Malard F, Mohty M, Bazarbachi A. Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant. Ther Adv Hematol. 2019;10:2040620719882666.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7:e724–36.
Byrne M, Danielson N, Sengsayadeth S, Rasche A, Culos K, Gatwood K, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020;95:1006–14.
Wojciechowski S, Tripathi P, Bourdeau T, Acero L, Grimes HL, Katz JD, et al. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J Exp Med. 2007;204:1665–75.
Lu P, Fleischmann R, Curtis C, Ignatenko S, Clarke SH, Desai M, et al. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus. 2018;27:290–302.
Khaw SL, Mérino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014;28:1207–15.
Malard F, Labopin M, Yakoub-Agha I, Chantepie S, Guillaume T, Blaise D, et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood. 2017;130:2186–95.
Acknowledgements
The authors acknowledge the clinical teams who provided care for the study patients, and the Tumorotheque of Saint-Antoine Hospital.
Author information
Authors and Affiliations
Contributions
All authors listed on the manuscript have contributed substantially to this work. LS, BG, MM, and FM designed the study, LS, BG, LR, NS and YY contributed the flow cytometry data, and LS and FM performed the statistical analysis. LS, BG, and FM prepared the manuscript and figures for publication.
Corresponding author
Ethics declarations
Conflict of interest
MM reports grants and/or lecture honoraria from Janssen, Sanofi, MaaT Pharma, JAZZ Pharmaceuticals, Celgene, Amgen, BMS, Takeda, Pfizer, and Roche. FM reports lecture honoraria from Therakos/Mallinckrodt, Biocodex, Janssen, Keocyt, Sanofi, JAZZ Pharmaceuticals, and Astellas, all outside the submitted work. The other authors did not disclose any relevant conflict of interest in relation to this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Siblany, L., Gaugler, B., Stocker, N. et al. Venetoclax does not impair activated T-cell proliferation. Bone Marrow Transplant 56, 1740–1742 (2021). https://doi.org/10.1038/s41409-021-01245-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-021-01245-6
This article is cited by
-
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Clinical Hematology International (2023)